BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huang L, Huang J, Huang J, Xue H, Liang Z, Wu J, Chen C. Nanomedicine - a promising therapy for hematological malignancies. Biomater Sci 2020;8:2376-93. [PMID: 32314759 DOI: 10.1039/d0bm00129e] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Hou Z, Zhou W, Guo X, Zhong R, Wang A, Li J, Cen Y, You C, Tan H, Tian M. Poly(ϵ-Caprolactone)-Methoxypolyethylene Glycol (PCL-MPEG)-Based Micelles for Drug-Delivery: The Effect of PCL Chain Length on Blood Components, Phagocytosis, and Biodistribution. IJN 2022;Volume 17:1613-32. [DOI: 10.2147/ijn.s349516] [Reference Citation Analysis]
2 Zoulikha M, He W. Targeted Drug Delivery for Chronic Lymphocytic Leukemia. Pharm Res. [DOI: 10.1007/s11095-022-03214-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Sochacka-Ćwikła A, Mączyński M, Regiec A. FDA-Approved Drugs for Hematological Malignancies-The Last Decade Review. Cancers (Basel) 2021;14:87. [PMID: 35008250 DOI: 10.3390/cancers14010087] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
4 Allegra A, Gioacchino MD, Tonacci A, Petrarca C, Gangemi S. Nanomedicine for Immunotherapy Targeting Hematological Malignancies: Current Approaches and Perspective. Nanomaterials (Basel) 2021;11:2792. [PMID: 34835555 DOI: 10.3390/nano11112792] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
5 Herdiana Y, Wathoni N, Shamsuddin S, Joni IM, Muchtaridi M. Chitosan-Based Nanoparticles of Targeted Drug Delivery System in Breast Cancer Treatment. Polymers (Basel) 2021;13:1717. [PMID: 34074020 DOI: 10.3390/polym13111717] [Cited by in Crossref: 2] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
6 Barani M, Bilal M, Rahdar A, Arshad R, Kumar A, Hamishekar H, Kyzas GZ. Nanodiagnosis and nanotreatment of colorectal cancer: an overview. J Nanopart Res 2021;23. [DOI: 10.1007/s11051-020-05129-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 19.0] [Reference Citation Analysis]
7 Sharmiladevi P, Girigoswami K, Haribabu V, Girigoswami A. Nano-enabled theranostics for cancer. Mater Adv 2021;2:2876-91. [DOI: 10.1039/d1ma00069a] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
8 Abd-Elrahman I, Nassar T, Khairi N, Perlman R, Benita S, Ben Yehuda D. Novel targeted mtLivin nanoparticles treatment for disseminated diffuse large B-cell lymphoma. Oncogene 2021;40:334-44. [PMID: 33128043 DOI: 10.1038/s41388-020-01529-z] [Reference Citation Analysis]
9 Cai M, Qin L, You L, Yao Y, Wu H, Zhang Z, Zhang L, Yin X, Ni J. Functionalization of MOF-5 with mono-substituents: effects on drug delivery behavior. RSC Adv 2020;10:36862-72. [DOI: 10.1039/d0ra06106a] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]